Etrasimod Reveals Promise in Moderate to Severe Ulcerative Colitis

Etrasimod, an investigational selective sphingosine 1-phosphate (S1P) receptor modulator, resulted in clinically meaningful improvements in sufferers with reasonably to severely active ulcerative colitis (UC), in step with an prognosis of two randomized trials.

In ELEVATE UC 52, the clinical remission fee used to be over three instances increased for individuals who acquired etrasimod when compared with placebo at 12 weeks (27% vs 7.4%) and over four instances increased at 52 weeks (32.1% vs 6.7%; P˂0.001 for every). In ELEVATE UC 12, the clinical remission fee used to be also increased (24.8% vs 15.2%, respectively, P=0.026), reported William J. Sandborn, MD, of the University of California San Diego.

In each trials, etrasimod also met all secondary efficacy endpoints, along with endoscopic enchancment, symptomatic remission, clinical response, and mucosal healing, among others, in step with findings presented at a leisurely-breaking presentation at the Digestive Disease Week annual meeting.

Identical remedy-emergent destructive occasions and serious destructive occasions took place among each remedy teams, with none original security findings for as much as 52 weeks in ELEVATE UC 52.

A old segment II trial from Sandborn and colleagues that evaluated etrasimod also confirmed efficacy in adults with moderate to extreme UC.

For their latest leer, Sandborn and group examined recordsdata from ELEVATE UC 52 (n=433) and ELEVATE UC 12 (n=354), two world segment III double-blind trials that enrolled adults with moderate to extreme UC from June 2019 to February 2022 and September 2020 to December 2021, respectively.

Both trials randomized sufferers 2:1 to receive oral etrasimod 2 mg once each day or placebo. Moderate or extreme disease assignment had been defined by a modified Mayo Rating (MMS) of 4 to 9 with a centrally be taught endoscopic subscore ≥2 and a rectal bleeding subscore ≥1, as smartly as documented history of inadequate response, lack of response, or an intolerance to now now not now now not as much as one UC remedy. Patients had been stratified in step with their baseline corticosteroid use and disease assignment (MMS 4-6 or 7-9), as smartly as to prior exposure to biologics or Janus kinase (JAK) inhibitors.

In ELEVATE UC 52, 433 sufferers had been randomized, and 207 done remedy through week 52. This leer consisted of a 12-week induction interval, followed by 40 weeks of remedy; if sufferers did now not abilities disease enchancment at 12 weeks, they had been in a location to cease and ticket up within the continuing originate-ticket extension leer, ELEVATE UC OLE, which at this time has about 912 sufferers enrolled and is anticipated to be done in August 2027. ELEVATE UC 12 consisted most efficient of a 12-week induction interval; 354 sufferers had been randomized and 316 done remedy through week 12.

Of those treated with etrasimod, 62.6% in each trials had been naive to biologics and JAK inhibitors, as had been 61.8% and 62.9% of placebo-treated sufferers, respectively.

Amongst each teams, remedy-emergent destructive occasions integrated COVID-19 infection, headache, worsening of UC, pyrexia, dizziness, arthralgia, nausea, and belly danger. No serious destructive occasions of atrioventricular block or bradycardia took place.

  • author['full_name']

    Zaina Hamza is a workers writer for MedPage This day, covering Gastroenterology and Infectious disease. She is predicated in Chicago.


Sandborn reported relationships with Alimentiv, Alivio Therapeutics, Allakos, Amgen, Enviornment Prescription tablets, AstraZeneca, Atlantic Prescription tablets, Bausch Properly being (Salix), BeiGene, Bellatrix Prescription tablets, Boehringer Ingelheim, Boston Prescription tablets, Bristol Myers Squibb, Celgene, Celltrion, ClostraBio, Codexis, Equillium, Forbion, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Immunic (Needed Therapies), Index Prescription tablets, Inotrem, Intact Therapeutics, Iota Biosciences, Janssen, Kiniksa Prescription tablets, Kyverna Therapeutics, Landos Biopharma, Lilly, Morphic Therapeutic, Novartis, Ono Prescription tablets, Oppilan Pharma (now Ventyx Biosciences), Otsuka, Pandion Therapeutics, and Pfizer, among diverse different entities.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button